Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Dr Mitchell recollected that there was no patient at Leicester with mild or moderate Haemophilia A or Haemophilia B, or with von Willebrand disorder who tested positive.

  • Read more about Dr Mitchell recollected that there was no patient at Leicester with mild or moderate Haemophilia A or Haemophilia B, or with von Willebrand disorder who tested positive.

An article was published in the Lancet regarding two patients treated with Armour heat-treated who developed NANB Hepatitis and a third treated with BPL's small pool heat-treated product..

  • Read more about An article was published in the Lancet regarding two patients treated with Armour heat-treated who developed NANB Hepatitis and a third treated with BPL's small pool heat-treated product..

The vast majority of treatment was with commercial concentrates, with very little NHS concentrate used. This was likely to have reflected the use of heat-treated concentrates.

  • Read more about The vast majority of treatment was with commercial concentrates, with very little NHS concentrate used. This was likely to have reflected the use of heat-treated concentrates.

Sheffield Centre switched to heat treated product occurred at the end of May 1984 along with three other centres.

  • Read more about Sheffield Centre switched to heat treated product occurred at the end of May 1984 along with three other centres.

There was a greater use of NHS concentrates than commercial, although a substantial amount of the latter (and a small amount of cryoprecipitate) was still used.

  • Read more about There was a greater use of NHS concentrates than commercial, although a substantial amount of the latter (and a small amount of cryoprecipitate) was still used.

The Sheffield Centre treated its patients with a mix of NHS concentrates and commercial.

  • Read more about The Sheffield Centre treated its patients with a mix of NHS concentrates and commercial.

A patient with mild/moderate haemophilia was treated with concentrates for elective surgery. The notes lacked detail to identify products used but "Dr Martin's statement confirms that no distinction was made at Alder Hey Hospital in terms of which product to prefer" vs what was available.

  • Read more about A patient with mild/moderate haemophilia was treated with concentrates for elective surgery. The notes lacked detail to identify products used but "Dr Martin's statement confirms that no distinction was made at Alder Hey Hospital in terms of which product to prefer" vs what was available.

Another child with mild haemophilia was treated with what appeared to be NHS Factor 8 in late 1982 and commercial Factor 8 between March and July 1983.

  • Read more about Another child with mild haemophilia was treated with what appeared to be NHS Factor 8 in late 1982 and commercial Factor 8 between March and July 1983.

A child born in 1980 (inferentially with severe haemophilia) "received a substantial amount of concentrate, the majority of it being commercial concentrate. The type of concentrate would have been dependant upon availability and treatment was standard." It was said that there was "Nothing atypical about treatment given to this Plaintiff."

  • Read more about A child born in 1980 (inferentially with severe haemophilia) "received a substantial amount of concentrate, the majority of it being commercial concentrate. The type of concentrate would have been dependant upon availability and treatment was standard." It was said that there was "Nothing atypical about treatment given to this Plaintiff."

A child with mild haemophilia had received commercial Factor VIII for a tooth extraction. This treatment "would not seem to be justified."

  • Read more about A child with mild haemophilia had received commercial Factor VIII for a tooth extraction. This treatment "would not seem to be justified."

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • Current page 32
  • Page 33
  • Page 34
  • Page 35
  • Page 36
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.